It's since revised its strategy. Latham-headquartered medical technology company AngioDynamics Inc. recently sold facilities in Queensbury and Glens Falls for a total of $6.65 million, according ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...

AngioDynamics, Inc.’s ANGO investors have been experiencing some short-term losses from the stock of late.Shares of the Latham, NY-based medical technology company have plunged 13.8% in the past ...

Across the recent three months, 4 analysts have shared their insights on AngioDynamics ANGO, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...

AngioDynamics has announced the receipt of new CPT Category I codes by the American Medical Association's CPT Editorial Panel ...

LATHAM, N.Y., December 09, 2024--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body ...

AngioDynamics Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner A downtrend has been apparent in AngioDynamics (NASDAQ: ANGO) lately with too much selling pressure ...

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...